Jenner & Block

 

Mr. Fogel's significant representative matters include:

  • Representing Coherus BioSciences in trade secret litigation concerning Udeynca, a biosimilar to Amgen’s Neulasta biological drug product that is used to treat neutropenia.
  • Represented Coherus BioSciences in patent litigation involving the manufacturing process for Udeynca, a biosimilar to Amgen’s Neulasta biological drug product that is used to treat neutropenia.  The case was dismissed with prejudice in 2018 and is currently on appeal.
  • Represented Coherus BioSciences in IPR proceedings related to patents covering AbbVie dosing regimens related to Humira.  All claims were invalidated in Final Written Decisions issued in May and June 2017.  The cases are currently on appeal.
  • Representing Ethicon, Inc. and Omrix Biopharmaceuticals in patent litigation involving hemostatic bandages.
  • Represented Johnson & Johnson and Cordis Corporation in patent litigation concerning the design and use of angioplasty catheters.
  • Represented Alza Corp. and McNeil-PPC Inc. in ANDA litigation involving Concerta, a drug used to treat attention deficit disorder.
  • Represented Kissei Pharmaceutical Co. in ANDA litigation involving Rapaflo, a drug used to treat benign prostatic hyperplasia (BPH).
  • Represented AstraZeneca in ANDA litigation involving Pulmicort Respules, a drug used to treat pediatric asthma.
  • Represented Genzyme in patent litigation concerning Fabrazyme, a drug produced by recombinant DNA technology that is used to treat Fabry disease.
  • Represented Wyeth Pharmaceuticals, Inc. in ANDA litigation involving Tygacil, a tetracycline class antibiotic.
  • Represented Wyeth Pharmaceuticals, Inc. in patent litigation concerning Refacto, a hemophilia drug produced by recombinant DNA technology.
  • Represented Schering Corp. in ANDA litigation concerning Zetia, a drug used to treat high cholesterol
  • Represented NEC Display Solutions of America, Inc. in patent litigation related to remote display advertising systems.
  • Represented a large international communications client in an ITC investigation, relating to multiple patents directed to features of wireless devices.